Difference between revisions of "Andexanet alfa (Andexxa)"
Jump to navigation
Jump to search
m |
m |
||
Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
Recombinant inactive FXa, used for specific reversal of DOACs (direct oral anticoagulants). | Recombinant inactive FXa, used for specific reversal of DOACs (direct oral anticoagulants). | ||
+ | |||
+ | =Preliminary data= | ||
+ | # Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41. Epub 2016 Aug 30. [http://www.nejm.org/doi/full/10.1056/NEJMoa1607887 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27573206 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] |
Revision as of 20:04, 21 May 2017
Mechanism of action
Recombinant inactive FXa, used for specific reversal of DOACs (direct oral anticoagulants).
Preliminary data
- Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41. Epub 2016 Aug 30. link to original article PubMed